Induction of chronic lymphocytic leukemia (CLL)–specific CD4- and CD8-mediated T-cell responses using RNA-transfected dendritic cells
- 1 March 2004
- journal article
- Published by American Society of Hematology in Blood
- Vol. 103 (5) , 1763-1769
- https://doi.org/10.1182/blood-2003-06-2097
Abstract
Recently, it was demonstrated that transfection of dendritic cells (DCs) with tumor-derived RNA can elicit effective T-cell responses. This technique does not require the definition of the tumor antigen or HLA haplotype of the patients. We applied this approach to induce HLA class I– and class II–restricted T-cell responses directed against malignant cells from patients with chronic lymphocytic leukemia (B-CLL). Here, we show that DCs generated from monocytes of patients with B-CLL induce leukemia-specific cytotoxic and proliferative T-cell responses on transfection with total RNA isolated from autologous leukemic B lymphocytes. Standard 51Cr-release assays showed specific major histocompatibility complex (MHC) class I–restricted cytotoxic activity against the autologous leukemic B cells and DCs transfected with CLL-RNA, whereas nonmalignant B cells were spared. The specificity of the cytotoxic T-lymphocyte (CTL) response was confirmed using cold target inhibition assays and by blocking HLA class I molecules. Furthermore, we established a protocol for the amplification of whole B-CLL mRNA. The use of DCs transfected with in vitro amplified B-CLL mRNA elicited specific T-cell responses similar to the results obtained with native mRNA. These data suggest that vaccinations using DCs transfected with RNA might be a potent new strategy in the treatment of CLL.Keywords
This publication has 48 references indexed in Scilit:
- Experience with alemtuzumab plus rituximab in patients with relapsed and refractory lymphoid malignanciesBlood, 2003
- Major histocompatibility complex class II‐restricted presentation of a cytosolic antigen by autophagyEuropean Journal of Immunology, 2003
- Rituximab in chronic lymphocytic leukemiaSeminars in Oncology, 2003
- Delivery of tumor-derived RNA for the induction of cytotoxic T-lymphocytesGene Therapy, 2003
- Induction of primary carcinoembryonic antigen (CEA)-specific cytotoxic T lymphocytes in vitro using human dendritic cells transfected with RNANature Biotechnology, 1998
- Bone marrow transplantation for low-grade B-cell malignanciesCurrent Opinion in Oncology, 1997
- Humanized CD52 monoclonal antibody campath‐1H as first‐line treatment in chronic lymphocytic leukaemiaBritish Journal of Haematology, 1996
- Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines.The Journal of Experimental Medicine, 1996
- REMISSION INDUCTION IN NON-HODGKIN LYMPHOMA WITH RESHAPED HUMAN MONOCLONAL ANTIBODY CAMPATH-1HThe Lancet, 1988
- Unusual T‐Cell Phenotype in Advanced B‐Chronic Lymphocytic LeukaemiaBritish Journal of Haematology, 1981